Addex Therapeutics Ltd Share Price Xetra
Stocks
APE
CH0029850754
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 2.82M 3.45M 2.97M 2.55M 4.79M 330M 4.81M 33.44M 12.86M 168M 12.96M 12.68M 530M | P/E 2024 |
0.8x | P/E 2025 | -0.88x |
|---|---|---|---|---|---|
| Enterprise Value | 1.21M 1.49M 1.28M 1.1M 2.06M 142M 2.07M 14.39M 5.54M 72.21M 5.58M 5.46M 228M | EV / Sales 2024 |
5.67x | EV / Sales 2025 | 28.1x |
| Free-Float |
43.94% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript : Addex Therapeutics Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Tim Dyer
CEO | Chief Executive Officer | 58 | 31/05/2013 |
Lénaic Teyssédou
DFI | Director of Finance/CFO | 40 | 31/05/2017 |
Roger Mills
CTO | Chief Tech/Sci/R&D Officer | 69 | 27/11/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Vincent Lawton
CHM | Chairman | 77 | - |
Tim Dyer
BRD | Director/Board Member | 58 | 31/12/2014 |
Ray Hill
BRD | Director/Board Member | 81 | 11/05/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -3.06% | - | - | 3.45M | |
| -0.71% | -6.35% | -2.99% | +9.37% | 45.48B | |
| +0.21% | -2.98% | +337.74% | +520.30% | 43.68B | |
| +1.74% | -2.24% | +39.82% | +20.85% | 43.09B | |
| +1.38% | -3.28% | +6.84% | +73.19% | 39.4B | |
| -1.44% | -5.26% | +8.97% | +39.76% | 31.91B | |
| +0.87% | -2.60% | - | - | 17.31B | |
| +0.75% | -0.64% | +19.75% | +108.58% | 16.4B | |
| -0.31% | -2.78% | +10.78% | +30.20% | 14.24B | |
| +1.93% | -3.55% | +82.00% | +36.66% | 13.28B | |
| Average | +0.44% | -3.20% | +62.86% | +104.87% | 29.42B | |
| Weighted average by Cap. | +0.41% | -3.50% | +74.57% | +124.86% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 410K 503K 433K 372K 697K 48.02M 701K 4.87M 1.87M 24.43M 1.89M 1.85M 77.19M | 173K 212K 183K 157K 294K 20.24M 295K 2.05M 789K 10.3M 796K 778K 32.54M |
| Net income | 7.06M 8.65M 7.45M 6.4M 12M 826M 12.06M 83.8M 32.23M 420M 32.48M 31.77M 1.33B | -6.73M -8.25M -7.11M -6.1M -11.44M -788M -11.5M -79.91M -30.73M -401M -30.97M -30.29M -1.27B |
| Net Debt | -3.3M -4.04M -3.48M -2.99M -5.61M -386M -5.64M -39.19M -15.07M -197M -15.19M -14.86M -621M | -1.6M -1.97M -1.69M -1.45M -2.73M -188M -2.74M -19.05M -7.33M -95.56M -7.38M -7.22M -302M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
